Latest News
Novartis Gene Therapies Releases Spring SMA Community Letter
Novartis Gene Therapies recently released an update to the SMA community related to clinical trials and long term follow up studies of Zolgensma, in addition to recent publications. Read the […]
Read More ›What is Spinal Muscular Atrophy
Table of Contents What is SMA How Common is SMA Types of SMA Causes of SMA Carrier Testing Symptoms of SMA Diagnosis SMA Newborn Screening Treatment for SMA Outlook / […]
Read More ›Cure SMA Attends Spring 2024 Professional Organization Conferences to Promote Findings from Industry Collaboration Initiatives
Cure SMA is pleased to announce the participation of scientific leadership in the 2024 Muscular Dystrophy Association (MDA) Virtual Clinical & Scientific Conference (March 3 – 6, 2024) and the […]
Read More ›SMA Community Advocacy Results in Key Accessible Air Travel Win
On May 16, after more than 2-years of advocacy and education by the SMA and disability communities, Cure SMA-supported legislation was signed into law making air travel safer and more […]
Read More ›HHS Action Improves Healthcare Accessibility and Strengthens Protections against Disability Discrimination in Healthcare
The U.S. Department of Health and Human Services (HHS) today finalized a rule to increase healthcare accessibility and strengthen federal protections against healthcare discrimination based on disability. The rule was […]
Read More ›Genentech Releases SMA Community Letter Recapping Spring Activities
On May 3, 2024, Genentech released an update to the SMA community related to Evrysdi® (risdiplam) and Genentech’s activities in service of the SMA community. Read the full community statement […]
Read More ›